FAKTOR-ZERTIFIKAT - BIOGEN IDEC | Real-time Bid/Ask 10:37:12 2024-05-23 am EDT | ||
| 4.45 EUR / 4.47 EUR | +20.22% |
|
| Current month | -51.38% | ||
| 1 month | -86.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 3.68 | -0.81% |
| 24-05-22 | 3.71 | +25.76% |
| 24-05-21 | 2.95 | -1.67% |
| 24-05-20 | 3 | -3.54% |
| 24-05-17 | 3.11 | +1.97% |
Delayed Quote Börse Stuttgart
Last update May 23, 2024 at 05:21 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | J.P. Morgan |
| WKN | JK4G0L |
| ISIN | DE000JK4G0L1 |
| Date issued | 2024-03-22 |
| Strike | 253 $ |
| Maturity | Unlimited |
| Parity | 7.39 : 1 |
| Emission price | 10.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.11 € |
|---|---|
| Lowest since issue | 2.52 € |
| Spread | 0.02 € |
| Spread % | 0.46% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
225.2
USD
Average target price
287.3
USD
Spread / Average Target
+27.57%
- Stock Market
- Certificates
- Certificat
